Description

Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity[1][2].–20°C (Powder, sealed storage, away from moisture)–Cancer-programmed cell death–C62H68F6N10O13—Am J Pathol. 2018 Apr;188(4):981-994.|Communications Medicine. 2, 80 (2022).|Hepatology. 2017 Oct;66(4):1197-1218.|Universidad De Salamanca. Biología y Clínica del Cáncer y Medicina Traslacional. 2022 Oct.|Basic Clin Pharmacol Toxicol. 2022 Jun 10.-[1]Lewis I, et, al. A novel somatostatin mimic with broad somatotropin release inhibitory factor receptor binding and superior therapeutic potential. J Med Chem. 2003 Jun 5;46(12):2334-44.|[2]Quinn TJ, et, al. Pasireotide (SOM230) is effective for the treatment of pancreatic neuroendocrine tumors (PNETs) in a multiple endocrine neoplasia type 1 (MEN1) conditional knockout mouse model. Surgery. 2012 Dec;152(6):1068-77.|[3]Imhof AK, et, al. Differential antiinflammatory and antinociceptive effects of the somatostatin analogs octreotide and pasireotide in a mouse model of immune-mediated arthritis. Arthritis Rheum. 2011 Aug;63(8):2352-62.—-1275.25–99.27–O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.NCCCC[C@@H](C(N[C@H]1CC2=CC=C(C=C2)OCC3=CC=CC=C3)=O)NC([C@H](NC([C@H](C4=CC=CC=C4)NC([C@H]5N(C([C@H](CC6=CC=CC=C6)NC1=O)=O)C[C@H](OC(NCCN)=O)C5)=O)=O)CC7=CNC8=C7C=CC=C8)=O–Endocrinology; Cancer–DMSO : 100 mg/mL (ultrasonic)|H2O : 33.33 mg/mL (ultrasonic)–Somatostatin Receptor—-GPCR/G Protein;Neuronal Signaling–Peptides